Real-time disaster intelligence, alerts, and response tools.
Wednesday, April 29, 2026
[ad_1] Findings published in Nature Biomedical Engineering and presented at ESMO 2025 validate iOncologi’s Universal Immune Fortifying RNAs (UNIFYRs™) as a new class of RNA therapeutics poised to transform cancer treatment. GAINESVILLE, Fla., Oct. 19, […]
[ad_1] – Results from the BL-B01D1-303 (NCT06118333) phase III trial presented in a late-breaking oral presentation at ESMO represents the first data readout for iza-bren from a registration enabling study in China REDMOND, Wash., Oct. […]
[ad_1] AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients […]
[ad_1] Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors beyond NSCLC in a Phase 2 cohort of the […]
[ad_1] More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in […]
